- Home
- GLMD vs SBFM Comparison
GLMD vs SBFM Comparison
Compare GLMD & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLMD | SBFM |
|---|---|---|
| Founded | 2000 | 2006 |
| Country | Israel | United States |
| Employees | N/A | 50 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 4.7M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | GLMD | SBFM |
|---|---|---|
| Price | $0.57 | $2.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 284.6K | ★ 8.3M |
| Earning Date | 05-21-2026 | 04-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $40.47 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $0.25 |
| 52 Week High | $2.34 | $3.05 |
Technical Indicators
Market Signals| Indicator | GLMD | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 46.03 | 60.63 |
| Support Level | $0.55 | $1.26 |
| Resistance Level | $0.69 | $2.18 |
| Average True Range (ATR) | 0.09 | 0.26 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 47.83 | 11.54 |
Price Performance
Historical ComparisonAbout GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.